Gland Pharma Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xmpddej6owr2lpj2hdqj30p8.pdf

Key Takeaways


Base Business Margin Expansion

Srinivas Sadu: "If you have seen last three to four quarters, we are actually improving our margins quarter-on-quarter basis because of the initiatives we have taken both from automation of lines, also from input materials and also from the operational efficiencies' perspective, working on the batch sizes and also looking at the bottlenecks where we can automate smaller things."

Cenexi Turnaround

Srinivas Sadu: "No, no, we do stick to that breakeven guidance for this quarter [Q3FY26]."

U.S. Business: Volume and Innovation-Led Growth

Srinivas Sadu: "If you look at the growth which came from last quarter also are from the launches, what we've done on the Specialty segment, CDMO launches that we have done, whether it's auto injectors or pendevice systems."

GLP-1 and Biologics Capacity Build

Shyamakant Giri: "So by mid of next year, we'll be having 14 crore capacity on cartridges, which makes us one of the top tier capacities here."

ROW and Other Markets


Guidance & Commitments

CommitmentSpecificsTimeline
Cenexi EBITDA breakevenEBITDA positive at EUR 50 million quarterly revenue; possibly breakeven at slightly lower revenueQ3 FY26
Consolidated revenue growthMid-teens growth on a consolidated basisFY26
Base business EBITDA marginTargeting around 35%; currently at 37%Ongoing
Consolidated gross margin74-75% on a sustainable basisFY26 full year
R&D expenseAround 5% of revenueAnnual basis
Base business capexApproximately ₹250 croreFY26
Base business capexApproximately ₹300 croreFY27
GLP-1 cartridge capacity14 crore unitsBy mid-next year
GLP-1 4 crore capacity ramp-upFull utilizationApproximately 2 years from early next year
Biologics CDMO capacityExpansion from 8 KL to 23 KLNext phase (undated)
Braine-l'Alleud freeze dryersQualification of two new freeze dryers completedEnd of 2025

Key Metrics

MetricQ2 FY26
Consolidated revenue₹1,486.9 crore, up 6% YoY
Consolidated EBITDA₹313.9 crore, up 6% YoY
Consolidated EBITDA margin21%
Consolidated net profit₹183.7 crore, PAT margin 12%, in line with Q2 FY25
Base business (ex-Cenexi) revenue₹1,076.7 crore
Base business adjusted EBITDA margin37%
U.S. revenue₹800.5 crore, up 8% YoY
Cenexi revenue€40 million, up 8% YoY; ₹410.2 crore, up 21% YoY in rupee terms
Cenexi H1 FY26 EBITDA loss€5 million, decreased from €11 million in H1 FY25
Consolidated gross margin63%, up from 59% in Q2 FY25
Base business gross margin61%, up from 56% in Q2 FY25
R&D expense₹61.4 crore, 5.8% of revenue, up from ₹49.3 crore in Q2 FY25
Other income₹84.2 crore, primarily from forex gains and interest on bank deposits
Cash flows from operations₹331.2 crore
Total cash and equivalents (group level, as of Sep 30, 2025)₹3,099.9 crore, including non-callable deposits of ₹396 crore
External debt at Cenexi level (as of Sep 30, 2025)₹254.4 crore
Average cash conversion cycle (H1 FY26)163 days, improved from 172 days at end of FY25
Capex (H1 FY26)₹196.9 crore, mainly deployed in Cenexi for new projects and capacity building
ANDAs filed in the quarter6
ANDA approvals received in the quarter5
New products launched in the U.S. in the quarter7
RTU bag products filed in the U.S.20 filed, 14 approved, 10 more in development, targeting an opportunity of roughly $659 million
Products under active development in high-potential categories15, including 7 505(b)(2) and 8 ANDAs
Biologic CDMO facility current capacity8 KL, with plan to expand to 23 KL
Cartridge fill/finish capacity expansionIncreasing from 4 crore to 14 crore units
Cenexi new project wins in the quarter4
Milestone revenue in the quarter~₹44-45 crore, versus a normal run rate of ~₹75-80 crore
Profit share for the quarter13%, compared to a general range of 9% to 10%
U.S. business volume growth (QoQ)10%, price almost flat, new launch contribution 7%
ROW own product sales growth (H1 FY26)19%, while tech transfer and CMO product revenue declined 53%
Standalone effective tax rate26%
Expected capex for Gland base business (full year FY26)Approximately ₹250 crore
Expected capex for Gland base business (FY27)Approximately ₹300 crore